What Did US FDA Do Wrong In Its Review Of Aducanumab? AdCom Members Have A List

 
• By Brenda Sandburg
Abstract mash line and point Question mark. Business illustration. Polygonal low poly
FDA Advisory Committee has many questions about aducanumab Alzheimer's disease drug • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers